文献速递肺结节与肺癌

Ifebemtinib联合garsorasib一线治疗KRASG12C突变NSCLC的1b/2期单臂扩展队列研究

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.
PubMed 文献 · Lancet Respir Med · 2026-07-07

该研究为在中国8个中心开展的多中心、单臂、Simon两阶段设计的1b/2期扩展队列,评估ifebemtinib(FAK抑制剂)联合garsorasib(KRASG12C抑制剂)一线治疗KRASG12C突变晚期NSCLC的安全性和疗效。

要点

  • 3-4级治疗相关不良事件发生率为24%(8/33),最常见为蛋白尿、腹泻、贫血、高血压和肺炎。
  • 该双口服无化疗方案显示出令人鼓舞的疗效和可控的安全性,随机3期试验已启动验证。

核心结论

  • ifebemtinib联合garsorasib双口服无化疗方案一线治疗KRASG12C突变NSCLC显示出令人鼓舞的疗效和可控的安全性。

研究设计与样本

  • 多中心、单臂、Simon两阶段设计的1b/2期扩展队列,在中国8个中心开展。
  • 纳入33例初治、ECOG评分0或1的KRASG12C突变局部晚期或转移性NSCLC成人患者。
  • 患者接受ifebemtinib 100 mg口服每日一次联合garsorasib 600 mg口服每日两次,21天为一周期。
  • 主要终点为研究者评估的客观缓解率(ORR),纳入所有接受至少一剂治疗的患者。

主要发现

  • 全部33例(100%)患者报告治疗中出现的不良事件,11例(33%)发生3-4级事件,其中8例(24%)与研究药物相关。
  • 最常见的3-4级治疗中出现不良事件为3级蛋白尿、腹泻、贫血、高血压和肺炎,各发生于2例(6%)患者。
  • 9例(27%)患者发生严重不良事件,颅内出血和肺炎各2例(6%),未报告治疗相关死亡。

临床怎么用

  • 对于初治KRASG12C突变晚期NSCLC患者,ifebemtinib联合garsorasib可作为潜在的一线双口服无化疗选择,但需关注3-4级不良事件尤其蛋白尿、腹泻、贫血、高血压和肺炎。
  • 该方案尚需随机3期试验(NCT07174908)进一步验证后方可常规推荐。

局限性

  • 单臂设计,无对照组,样本量较小(33例)。
  • 仅纳入中国患者,ECOG评分0-1,外推性受限。
  • 随访时间仍有限,无进展生存期和总生存期数据未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ifebemtinib, a potent selective oral inhibitor of FAK, has shown preclinical synergistic activity with KRASG12C inhibitors. Garsorasib is a novel KRASG12C inhibitor approved in China for patients with KRASG12C-mutated non-small-cell lung cancer (NSCLC). This study aimed to evaluate the safety and efficacy of ifebemtinib plus garsorasib in KRASG12C-mutated solid tumours. METHODS: This multicentre study had a phase 1b component to establish the recommended phase 2 dose and a phase 2 multitumour expansion. Here, we report the results of the single-arm, Simon's two-stage cohort of first-line KRASG12C-mutated NSCLC from phase 2 expansion. The study was conducted at eight sites in China. Eligible patients were adults with pathologically confirmed locally advanced or metastatic NSCLC who were harbouring a KRASG12C mutation, were treatment-naive, and had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Enrolled patients received ifebemtinib (100 mg orally once a day) in combination with garsorasib (600 mg orally twice a day) in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent, initiation of new therapies, or death. The primary endpoint was objective response rate (ORR), as assessed by investigators, in all patients who received at least one dose of study treatment. The same population was included in safety analyses. This study is registered with ClinicalTrials.gov (NCT06166836 and NCT05379946) and is active but not recruiting. FINDINGS: Between April 21, 2023, and Dec 27, 2023, 33 first-line patients with NSCLC (two [6%] female and 31 [94%] male) were enrolled and received at least one dose of ifebemtinib plus garsorasib. As of Sept 16, 2025, median follow-up duration was 21·5 months (IQR 21·0-23·9). Confirmed ORR was 82% (27 of 33 patients; 95% CI 64·5-93·0). All 33 (100%) patients reported treatment-emergent adverse events, with 11 (33%) patients experiencing grade 3 or 4 events, of which eight (24%) were related to study drugs. The most frequent treatment-emergent adverse events of grade 3-4 were grade 3 proteinuria, diarrhoea, anaemia, hypertension, and pneumonia, each occurring in two (6%) of 33 patients. Serious adverse events occurred in nine (27%) of 33 patients, with intracranial haemorrhage and pneumonia being the only events reported in at least two patients (two [6%] each). No treatment-related deaths were reported. INTERPRETATION: The dual-oral chemotherapy-free regimen of ifebemtinib plus garsorasib had encouraging efficacy with a manageable safety profile as first-line treatment for KRASG12C-mutated NSCLC. A randomised phase 3 study has been initiated to further validate these findings against standard-of-care in the first-line setting (NCT07174908). FUNDING: InxMed, InventisBio, the National Natural Science Foundation of China, the Jian Bing Ling Yan + X Research and Development Programme of Zhejiang Province, and the Zhejiang Province Medical and Health Science and Technology Plan Project.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Song Z, Li X, Lin R, et al. Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial. Lancet Respir Med. 2026. PMID: 42413526. doi:10.1016/S2213-2600(26)00142-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。